ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "B cells"

  • Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting

    Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity

    Hao Li1, Hui-Chen Hsu2, Qi Wu3, Jun Li3, PingAr Yang3, Yang-Xin Fu4 and John D. Mountz5, 1Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, 2Birmingham VA Medical Center, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Department of Pathology, The University of Chicago, Chicago, IL, 5Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…
  • Abstract Number: 1743 • 2013 ACR/ARHP Annual Meeting

    Administration Of AMG 557, a Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE:  Results Of a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study

    Barbara Sullivan1, Wayne H. Tsuji2, Vishala L. Chindalore3, Thomas D. Geppert4, Alla Rudinskaya5, Patricia Pardo6, Alan Kivitz7, C. Michael Neuwelt8, Meggan Mackay9, R. John Looney10, J. Carter Thorne11, Marilee Andrew12, Greg Arnold13, Michael Boedigheimer1, Kit Chiu1, Cherie Green1, Arunan Kaliyaperumal1, Christine Wang14, Andrew Welcher1 and James Chung1, 1Amgen, Thousand Oaks, CA, 2Clinical Research/Inflammation, Amgen, Seattle, WA, 3Anniston Medical Clinic PC, Anniston, AL, 4Metroplex Clinical Research Center, LLC, Dallas, TX, 5Danbury Hospital, Danbury, CT, 6MRA Clinical Research, Miami, FL, 7Altoona Center for Clinical Research, Duncansville, PA, 8East Bay Rheumatology Research Institute, San Leandro, CA, 9Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, 10Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12Amgen, Seattle, WA, 13Medical Sciences, Amgen, Thousand Oaks, CA, 14Biostatistics, Amgen, Thousand Oaks, CA

    Background/Purpose: The interaction of inducible costimulator (ICOS) with its ligand, B7-related protein-1 (B7RP-1 or ICOSL), plays a role in T cell differentiation, cytokine production, and…
  • Abstract Number: 890 • 2013 ACR/ARHP Annual Meeting

    Quantitative Cell Distance Mapping In Human Nephritis Reveals Organization Of In Situ Adaptive Immune Responses

    Marcus R. Clark1, Vladimir M. Liarski1, Natalya Kavernia2, Maryellen L. Giger3, Anthony Chang4, Yahui Peng3 and Daniel F. Brandt2, 1Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, 2Rheumatology, University of Chicago, Chicago, IL, 3Radiology, University of Chicago, Chicago, IL, 4Pathology, University of Chicago, Chicago, IL

    Background/Purpose: Inflammatory infiltrates contain multiple cell types that could interact in myriad ways to amplify in situ immune responses. However, there currently are no methods…
  • Abstract Number: 38 • 2013 ACR/ARHP Annual Meeting

    Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus

    Venkat Reddy1, Geraldine Cambridge2, D.A. Isenberg3, Mark Cragg4 and Maria Leandro5, 1Rheumatology, University College London, London, United Kingdom, 2Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 3Centre for Rheumatology Research, University College London, London, United Kingdom, 4Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom, 5Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor…
  • Abstract Number: 172 • 2013 ACR/ARHP Annual Meeting

    Transcript Profiling Of Kidney Biopsies From Chinese Patients With Lupus Nephritis Suggests a Prevalence Of Infiltrating CD8+ T Cells, Monocytes/Macrophages, and B Cells In ISN/RPS Class IV Disease

    Zheng Liu1, Chris Morehouse1, Xinfang Huang2, Philip Brohawn1, Nan Shen3, Gabor G. Illei4, Yihong Yao1 and Brandon W. Higgs1, 1Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 2Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 3Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, cincinnati, OH, 4Clinical Development, MedImmune, LLC, Gaithersburg, MD

    Transcript profiling of kidney biopsies from Chinese patients with lupus nephritis suggests a prevalence of infiltrating CD8+ T cells, monocytes/macrophages, and B cells in ISN/RPS…
  • Abstract Number: 1665 • 2013 ACR/ARHP Annual Meeting

    B Cells Revisited In Giant Cell Arteritis

    Kornelis S.M. van der Geest1, Wayel H. Abdulahad2, Gerda Horst2, Caroline Roozendaal3, Abraham Rutgers2, Annemieke M.H. Boots2 and Elisabeth Brouwer2, 1Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 3Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) is a primary vasculitis affecting large to medium-sized arteries. Ample evidence suggests that dendritic cells, T cells and monocytes/macrophages contribute…
  • Abstract Number: 705 • 2013 ACR/ARHP Annual Meeting

    Treatment With Rituximab Reduces Activation Of Scleroderma Dermal Fibroblasts

    Paolo Fraticelli1, Salvatore De Vita2, Nicoletta Franzolini3, Silvia Svegliati4, Cecilia Tonnini4, Barbara Gabrielli5, Cathryn Anne Scott6, Giovanni Pomponio7, Gianluca Moroncini4 and Armando Gabrielli4, 1Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, 2Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, 3Presidio Ospedaliero di San Daniele del Friuli, ASS 4 “Medio Friuli, Udine, Italy, 4Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, 5Università Politecnica delle Marche, Ancona, Italy, 6Department of Medical and Biological Sciences, Università degli studi di Udine ·, Udine, Italy, 7Medicina Interna, Ospedali Riuniti, Ancona, Italy

    Background/Purpose:  There is evidence that B lymphocytes play a role in the pathogenesis  of systemic sclerosis (scleroderma). Stimulatory autoantibodies targeting PDGF receptor and activating normal…
  • Abstract Number: L16 • 2013 ACR/ARHP Annual Meeting

    Kidney Resident B Cells and Plasmacytoid Dendritic Cells  in Urine of Systemic Lupus Erythematosus  patients

    Eric Scott1, Mary Anne Dooley2 and Steve Clarke1, 1Microbiology/Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC

    Title: Kidney resident B Cells and plasmacytoid dendritic cells (pDCs) in the urine of systemic lupus erythematosus (SLE) patients. Background/Purpose: Renal involvement remains the principal…
  • Abstract Number: 1629 • 2013 ACR/ARHP Annual Meeting

    Functional Effect Of NR1H3 (LXRA) Promoter Polymorphisms In Korean Patients With Systemic Lupus Erythematosus

    Ja-Young Jeon1, Hyoun-Ah Kim1, Ju-Yang Jung1 and Chang-Hee Suh2, 1Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 2Department of Rheumatology, Ajou University Hospital, Suwon, South Korea

    Background/Purpose: Liver X receptor alpha (LXRA, NR1H3) and beta (LXRB, NR1H2) can influence macrophage biology by modulation of lipid metabolism and by effects on innate…
  • Abstract Number: 636 • 2013 ACR/ARHP Annual Meeting

    Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow

    Anna Bird1, Nida Meednu2, Javier Rangel-Moreno3, Srilakshmi Yalavarthi4, Jennifer Barnard1, Teresa Owen5, Jason S. Knight6, Alfred Rabinovich1, Arumugam Palanichamy2, Jane Liesveld7, Jason W Bauer8, Emily Baechler9, Mariana J. Kaplan10 and Jennifer H. Anolik11, 1Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 3Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, 4University of Michigan Rheumatology, Ann Arbor, MI, 5Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, 6Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 7Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, 8University of Minnesota, Minneapolis, MN, 9Medicine, University of Minnesota, Minneapolis, MN, 10Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, 11Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose: Although SLE is known to be associated with a type I interferon signature in the peripheral blood, the precise site and mechanism of IFN…
  • Abstract Number: 2319 • 2012 ACR/ARHP Annual Meeting

    T Follicular Helper Cell and Regulatory T Cell Frequencies Are Affected by B Cell Depletion in Patients with Granulomatosis with Polyangiitis

    Yuan Zhao1, Jessica Thomas1, Shirish Sangle2, Pamela M.K Lutalo3, Lee Meng Choong4, Jennifer R. Tyler1, Jo Spencer5, Timothy Tree6 and David P. D'Cruz2, 1Peter Gorer Department of Immunobiology, School of Medicine, King's College London, London, United Kingdom, 2Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, 3Louise Coote Lupus Unit, St Thomas Hospital, London, United Kingdom, 4Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, 5Peter Gorer Department of Immunobiology, King's College London, School of Medicine, London, United Kingdom, 6national Institute of Health Research Centre at Guy's and St Thomas' NHS Trust, School of Medicine, King's College London, London, United Kingdom

    Background/Purpose:  Granulomatosis with polyangiitis (GPA, formerly known as Wegener's granulomatosis) is a rare and sometimes fatal systemic autoimmune disease. Anti-neutrophil cytoplasmic antibodies (ANCAs) specific for…
  • Abstract Number: 1744 • 2012 ACR/ARHP Annual Meeting

    Regulatory B Cells Supress the Progression of Fatal Autoimmunity in Lupus-Prone Mice

    Yuriy Baglaenko1, Nan-Hua Chang2, Evelyn Pau3 and Joan E. Wither4, 1Immunology, University of Toronto, Toronto, ON, Canada, 2Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 41E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disorder characterized by the production of anti-nuclear antibodies (ANA) which form immune complexes and promote…
  • Abstract Number: 679 • 2012 ACR/ARHP Annual Meeting

    ZAP70+ B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis

    Elisa Gremese, Barbara Tolusso, Laura Messuti, Marcin Nowik, Silvia Canestri, Luca Petricca, Maria Rita Gigante and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: To analyze differences in B cells subsets distribution in patients with renal systemic lupus erythematosus (SLE). To define  possible cellular biomarkers of active nephritis…
  • Abstract Number: 2668 • 2012 ACR/ARHP Annual Meeting

    Interferon and B-Cell Gene Signatures Contribute to Diagnosis of  pre-Clinical Rheumatoid Arthritis

    Joyce Lubbers1, Lotte A. van de Stadt2, Saskia Vosslamber1, John G. Wesseling1, Dirkjan van Schaardenburg2 and Cornelis L. Verweij3, 1Pathology, VU University Medical Center, Amsterdam, Netherlands, 2Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 3Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Diagnosis of the preclinical phase of rheumatoid arthritis (pre-RA) allows timely start of treatment with the potential to prevent disease progression. It is known…
  • Abstract Number: 2197 • 2012 ACR/ARHP Annual Meeting

    Diagnostic Value of Blood B-Cell Subset Profiling and Autoimmunity Markers in Anti-SSA-Negative Sjögren’s Syndrome Patients

    Divi Cornec1, Alain Saraux2, Jacques-Olivier Pers3, Sandrine Jousse-Joulin4, Yves Renaudineau3, Thierry Marhadour5 and Valerie Devauchelle-Pensec6, 1Department of rheumatology, Brest Occidentale University, Brest, France, 2Department of rheumatology and unit of immunology (EA 2216), Brest Occidentale university, Brest, France, 3Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 4Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, 5Rheumatology, CHU de la Cavale Blanche, Brest, France, 6Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France

    Background/Purpose: Recently published ACR classification criteria for primary Sjögren’s syndrome (pSS) suggest considering antinuclear antibodies (ANA) titer and rheumatoid factor (RF) positivity in patients negative…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology